Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Diagnostic Pathology
Published in: Diagnostic Pathology 1/2013

Open Access 01-12-2013 | Research

Expression and clinical significance of the proliferation marker minichromosome maintenance protein 2 (Mcm2) in diffuse astrocytomas WHO grade II

Authors: Tove Lind-Landström, Rosilin K Varughese, Stein Sundstrøm, Sverre H Torp

Published in: Diagnostic Pathology | Issue 1/2013

Login to get access

Abstract

Background

The WHO classification system for astrocytomas is not considered optimal, mainly because of the subjective assessment of the histopathological features. Few prognostic variables have been found that stratify the risk of clinical progression in patients with grade II astrocytoma. For that reason there is a continuous search for biomarkers that can improve the histopathological diagnosis and prognostication of these tumours.

Aim

This study was designed to investigate the prognostic significance of the proliferative marker Mcm2 (minichromosome maintenance protein 2) in diffuse astrocytomas WHO grade II and correlate the findings with histopathology, mitoses, and Ki67/MIB-1 immunostaining.

Method

61 patients with histologically verified grade II astrocytoma (WHO 2007) were investigated. Paraffin sections were immunostained with anti-Mcm2, and the Mcm2 proliferative index (PI) was determined as the percentage of immunoreactive tumour cell nuclei.

Results

Mcm2 PI was not associated with any histopathological features but correlated significantly with mitotic count and Ki67/MIB-1 PI (p<0.05). In the survival analyses Mcm2 showed trends to poorer survival, however, statistical significance was not achieved in the univariate analyses (p>0.05).

Conclusions

In our hands Mcm2 immunostaining has no advantage over Ki67/MIB-1 in the evaluation of grade II astrocytomas. Larger studies are needed to fully clarify the prognostic role of this biomarker.

Virtual slides

The virtual slide(s) for this article can be found here: http://​www.​diagnosticpathol​ogy.​diagnomx.​eu/​vs/​1715002791944037​
Appendix
Available only for authorised users
Literature
1.
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK: WHO Classification of Tumours of the Central Nervous System. 2007, IARC: Lyon, 4
2.
Jansen M, Yip S, Louis DN:Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol. 2010, 9: 717-726. 10.1016/S1474-4422(10)70105-8.PubMedCentralCrossRefPubMed
3.
Gomori E, Pal J, Kovacs B, Doczi T: Concurrent hypermethylation of DNMT1. MGMT and EGFR genes in progression of gliomas. Diagn Pathol. 2012, 7: 8-10.1186/1746-1596-7-8.PubMedCentralCrossRefPubMed
4.
Gulati S, Ytterhus B, Granli US, Gulati M, Lydersen S, Torp SH: Overexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas. Diagn Pathol. 2010, 5: 18-10.1186/1746-1596-5-18.PubMedCentralCrossRefPubMed
5.
Habberstad AH, Gulati S, Torp SH: Evaluation of the proliferation markers Ki-67/MIB-1, mitosin, survivin, pHH3, and DNA topoisomerase IIalpha in human anaplastic astrocytomas–an immunohistochemical study. Diagn Pathol. 2011, 6: 43-10.1186/1746-1596-6-43.PubMedCentralCrossRefPubMed
6.
Cavalla P, Schiffer D: Cell cycle and proliferation markers in neuroepithelial tumors. Anticancer Res. 1997, 17: 4135-4143.PubMed
7.
Prayson RA: Cell proliferation and tumors of the central nervous system. Part 1: Evaluation of mitotic activity. J Neuropathol Exp Neurol. 2002, 61: 501-509.PubMed
8.
Prayson RA: Cell proliferation and tumors of the central nervous system, part II: radiolabeling, cytometric, and immunohistochemical techniques. J Neuropathol Exp Neurol. 2002, 61: 663-672.PubMed
9.
Johannessen AL, Torp SH: The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. Pathol Oncol Res. 2006, 12: 143-147. 10.1007/BF02893360.CrossRefPubMed
10.
WHO: Classification Tumours of the Nervous System. 2007, Lyon: IARC, 4
11.
Cattoretti G, Becker MH, Key G, Duchrow M, Schluter C, Galle J, Gerdes J: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol. 1992, 168: 357-363. 10.1002/path.1711680404.CrossRefPubMed
12.
Hsu DW, Louis DN, Efird JT, Hedley-Whyte ET: Use of MIB-1 (Ki-67) immunoreactivity in differentiating grade II and grade III gliomas. J Neuropathol Exp Neurol. 1997, 56: 857-865. 10.1097/00005072-199708000-00003.CrossRefPubMed
13.
Prayson RA: The utility of MIB-1/Ki-67 immunostaining in the evaluation of central nervous system neoplasms. Adv Anat Pathol. 2005, 12: 144-148. 10.1097/01.pap.0000163957.21409.52.CrossRefPubMed
14.
Taran K, Sitkiewicz A, Andrzejewska E, Kobos J: Minichromosome maintenance 2 (MCM2) is a new prognostic proliferative marker in Wilms tumour. Pol J Pathol. 2011, 62: 84-88.PubMed
15.
Freeman A, Morris LS, Mills AD, Stoeber K, Laskey RA, Williams GH, Coleman N: Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res. 1999, 5: 2121-2132.PubMed
16.
Wharton SB, Chan KK, Anderson JR, Stoeber K, Williams GH: Replicative Mcm2 protein as a novel proliferation marker in oligodendrogliomas and its relationship to Ki67 labelling index, histological grade and prognosis. Neuropathol Appl Neurobiol. 2001, 27: 305-313. 10.1046/j.0305-1846.2001.00333.x.CrossRefPubMed
17.
Hunt DP, Freeman A, Morris LS, Burnet NG, Bird K, Davies TW, Laskey RA, Coleman N: Early recurrence of benign meningioma correlates with expression of mini-chromosome maintenance-2 protein. Br J Neurosurg. 2002, 16: 10-15. 10.1080/02688690120114174.CrossRefPubMed
18.
Lind-Landstrom T, Habberstad AH, Torp SH: Proliferative activity and histopathological features in diffuse grade II astrocytomas. APMIS. 2012, 120: 640-647. 10.1111/j.1600-0463.2012.02881.x.CrossRefPubMed
19.
Lind-Landstrom T, Habberstad AH, Sundstrom S, Torp SH: Prognostic value of histological features in diffuse astrocytomas WHO grade II. Int J Clin Exp Pathol. 2012, 5: 152-158.PubMed
20.
Margraf LR, Gargan L, Butt Y, Raghunathan N, Bowers DC: Proliferative and metabolic markers in incompletely excised pediatric pilocytic astrocytomas–an assessment of 3 new variables in predicting clinical outcome. Neuro Oncol. 2011, 13: 767-774. 10.1093/neuonc/nor041.PubMedCentralCrossRefPubMed
21.
Wojnar A, Kobierzycki C, Krolicka A, Pula B, Podhorska-Okolow M, Dziegiel P: Correlation of Ki-67 and MCM-2 proliferative marker expression with grade of histological malignancy (G) in ductal breast cancers. Folia Histochem Cytobiol. 2010, 48: 442-446.CrossRefPubMed
22.
Werynska B, Pula B, Muszczynska-Bernhard B, Piotrowska A, Jethon A, Podhorska-Okolow M, Dziegiel P, Jankowska R: Correlation between expression of metallothionein and expression of Ki-67 and MCM-2 proliferation markers in non-small cell lung cancer. Anticancer Res. 2011, 31: 2833-2839.PubMed
23.
Hanna-Morris A, Badvie S, Cohen P, McCullough T, Andreyev HJ, Allen-Mersh TG: Minichromosome maintenance protein 2 (MCM2) is a stronger discriminator of increased proliferation in mucosa adjacent to colorectal cancer than Ki-67. J Clin Pathol. 2009, 62: 325-330. 10.1136/jcp.2007.054643.CrossRefPubMed
24.
Seidal T, Balaton AJ, Battifora H: Interpretation and quantification of immunostains. Am J Surg Pathol. 2001, 25: 1204-1207. 10.1097/00000478-200109000-00013.CrossRefPubMed
25.
Torres-Rendon A, Roy S, Craig GT, Speight PM: Expression of Mcm2, geminin and Ki67 in normal oral mucosa, oral epithelial dysplasias and their corresponding squamous-cell carcinomas. Br J Cancer. 2009, 100: 1128-1134. 10.1038/sj.bjc.6604967.PubMedCentralCrossRefPubMed
26.
Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984, 133: 1710-1715.PubMed
27.
Brat DJ, Prayson RA, Ryken TC, Olson JJ: Diagnosis of malignant glioma: role of neuropathology. J Neurooncol. 2008, 89: 287-311. 10.1007/s11060-008-9618-1.CrossRefPubMed
28.
29.
Hall PA, Coates PJ: Assessment of cell proliferation in pathology–what next?. Histopathology. 1995, 26: 105-112. 10.1111/j.1365-2559.1995.tb00639.x.CrossRefPubMed
30.
Schiffer D, Cavalla P, Chio A, Richiardi P, Giordana MT: Proliferative activity and prognosis of low-grade astrocytomas. J Neurooncol. 1997, 34: 31-35. 10.1023/A:1005755119526.CrossRefPubMed
Metadata
Title
Expression and clinical significance of the proliferation marker minichromosome maintenance protein 2 (Mcm2) in diffuse astrocytomas WHO grade II
Authors
Tove Lind-Landström
Rosilin K Varughese
Stein Sundstrøm
Sverre H Torp
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2013
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/1746-1596-8-67

Other articles of this Issue 1/2013

Diagnostic Pathology 1/2013 Go to the issue

Case Report

Thyroid nodule as a first manifestation of Hodgkin lymphoma–report of two cases and literature review

Case Report

Multiple peripheral typical carcinoid tumors of the lung: associated with sclerosing hemangiomas

Case Report

Sudden death of an infant with cardiac, nervous system and genetic involvement – a case report

Debate

Parapharyngeal liposarcoma: a case report

Case Report

Solitary myofibroma of the sigmoid colon: case report and review of the literature

Short report

Frequency of D222G haemagglutinin mutant of pandemic (H1N1) pdm09 influenza virus in Tunisia between 2009 and 2011